Stock Evaluator: AtaiBeckley Inc. (ATAI)

AtaiBeckley Inc. ATAI

$7.18 0.00 0.00%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 8,914,601
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Commentary & Analysis


Financial Summary

Share Statistics ATAI Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $2,656.3 $579.1 58%
Shares Out (Mil) 357.4 43.0 85%
Institutional Ownership 93.9% 84.3% 64%
Float (Mil) 307.4 46.8 80%
Beta 1.61 0.62 85%
Avg Daily Volume (000s) 13,246 285 97%
Price Change
(52-week)
106.9% 63.8% 92%
Growth ATAI Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) (31.2%) (1.4%) 13%
EPS (5yr) (9.8%) 14.9% 21
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (18.4%) (14.9%) 37%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 9 10 8
Current EPS ($0.112) ($0.433) ($0.456)
Month Ago EPS ($0.114) ($0.440) ($0.455)
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.125) ($0.485) ($0.501)
Year/Year Chg 34.9% (85.1%) (83.7%)
Financials ATAI Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $4 $272 5%
Net Income (TTM) (Mil) ($663) ($11) 2%
EPS (TTM) ($2.441) ($0.500) 13%
Operating Cash Flow (TTM) (Mil) ($106) ($6) 6%
Net Cash Flow (TTM) (Mil) ($15) $4 28%
Long-Term Debt (Q1) (Mil) $2 $7 21%
Enterprise Value (Q1) (Mil) $1,166 $522 43%
Valuation ATAI Industry
Median
Percentile
(All Stocks)
P/B 13.30 2.73 93%
P/E na 20.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios ATAI Industry
Median
Percentile
(All Stocks)
Gross Margin na 65.9% na
Net Margin na 0.7% na
ROA (288.0%) (24.6%) 1%
ROE (378.3%) (19.7%) 2%
Liabilities to Assets 25.0% 35.5% 17%
F-Score 4 3 34%

AtaiBeckley Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors